Our Q3 2013 Outlook Report highlighted several high-impact catalysts that resulted in large stock price changes. The results of all of our Q3 catalysts can be found on Page 4 of this report. BioMedTracker Likelihood of Approval (LOA) opinions successfully predicted 70% of catalyst outcomes in Q3 2013.

In this quarter's report, we cover a number of catalysts from 17 drugs and 2 devices. Included in this report, from our sister product, CatalystTracker, is a list of Large Impact catalysts in the drug, device/diagnostic, and natural resource areas through December 2013. With each upcoming event set to occur in Q4 below, we have included the drugs’ likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group. Please note the current LOAs displayed on BioMedTracker are not based on these new probabilities; these new data will be integrated at a later time.

If you would like a copy of the calendars in Excel, please email clientservices@pharmaintel.informa.com or contact your sales representative For the full report, please download the PDF version at the top of this page. For our disclosures, please read the BioMedTracker Research Standards.